Q32 Bio (NASDAQ:QTTB) Trading Down 3.8% - What's Next?

Key Points

• Shares down 3.8% — Q32 Bio fell to $5.50 on Wednesday with 147,538 shares traded (about 43% below average); the stock has a 50‑day MA of $5.83 and a market cap of $80.46M.
• Analyst views are mixed but consensus is a “Moderate Buy” with an average price target of $13.00, ranging from Sell to Strong Buy across three recent reports.
• Strong quarterly beat — Q32 reported $3.65 EPS vs. a -$1.06 estimate and $53.74M revenue, yet analysts still forecast -2.57 EPS for the year and insiders (including the CEO) have sold shares recently.

Q32 Bio Inc. (NASDAQ:QTTB - Get Free Report) shares fell 3.8% during trading on Wednesday . The company traded as low as $5.38 and last traded at $5.50. 147,538 shares were traded during mid-day trading, a decline of 43% from the average session volume of 258,342 shares. The stock had previously closed at $5.72.

Analyst Upgrades and Downgrades

A number of research firms recently commented on QTTB. Zacks Research upgraded shares of Q32 Bio from a "hold" rating to a "strong-buy" rating in a research report on Thursday, March 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Q32 Bio in a research report on Friday, January 9th. Finally, HC Wainwright restated a "buy" rating and issued a $13.00 price objective on shares of Q32 Bio in a research report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Q32 Bio currently has an average rating of "Moderate Buy" and an average price target of $13.00.

Q32 Bio Stock Performance

The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.85 and a current ratio of 4.85. The stock's 50-day moving average is $5.83 and its 200 day moving average is $4.12. The firm has a market cap of $80.46 million, a P/E ratio of 2.39 and a beta of -0.05.

Q32 Bio (NASDAQ:QTTB - Get Free Report) last released its quarterly earnings data on Tuesday, March 10th. The company reported $3.65 EPS for the quarter, beating analysts' consensus estimates of ($1.06) by $4.71. The firm had revenue of $53.74 million during the quarter. On average, research analysts predict that Q32 Bio Inc. will post -2.57 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Jodie Pope Morrison sold 9,896 shares of the company's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total value of $44,630.96. Following the completion of the transaction, the chief executive officer directly owned 89,104 shares of the company's stock, valued at approximately $401,859.04. This represents a 10.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 16,706 shares of company stock valued at $75,344. 40.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Q32 Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new position in Q32 Bio in the 4th quarter worth $68,000. Jane Street Group LLC acquired a new position in Q32 Bio in the 4th quarter worth $84,000. Renaissance Technologies LLC boosted its stake in Q32 Bio by 110.6% in the 4th quarter. Renaissance Technologies LLC now owns 99,600 shares of the company's stock worth $331,000 after purchasing an additional 52,300 shares during the period. Opaleye Management Inc. acquired a new position in Q32 Bio in the 4th quarter worth $708,000. Finally, Geode Capital Management LLC boosted its stake in Q32 Bio by 19.9% in the 4th quarter. Geode Capital Management LLC now owns 106,113 shares of the company's stock worth $352,000 after purchasing an additional 17,617 shares during the period. 31.32% of the stock is owned by institutional investors and hedge funds.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.